Your browser doesn't support javascript.
loading
[Icariin inhibits thioacetamide-induced osteoclast differentiation through RANKL-p38/ERK-NFAT pathway].
Cheng, Lin-Yan; Jin, Xiao-Li; Chen, Xuan-Wei; Chen, Jin; Ren, Jun; Huang, Hui; Xu, Jian.
Affiliation
  • Cheng LY; School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University Hangzhou 310053, China.
  • Jin XL; School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University Hangzhou 310053, China.
  • Chen XW; School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University Hangzhou 310053, China.
  • Chen J; School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University Hangzhou 310053, China.
  • Ren J; School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University Hangzhou 310053, China.
  • Huang H; School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University Hangzhou 310053, China.
  • Xu J; School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University Hangzhou 310053, China.
Zhongguo Zhong Yao Za Zhi ; 47(21): 5882-5889, 2022 Nov.
Article in Zh | MEDLINE | ID: mdl-36472007
This study aims to investigate the therapeutic effect of icariin(ICA) on thioacetamide(TAA)-induced femoral osteolysis in rats. RAW264.7 cells were treated with TAA and ICA. Cell counting kit-8(CCK-8) assay was used to detect cell proliferation, and tartrate-resistant acid phosphatase(TRAP) staining to examine the formation of osteoclasts. The expression of TRAP, cathepsin K, c-FOS, and NFATc1 in RAW264.7 cells was determined by Western blot and immunofluorescence method. Thirty-two SD rats were randomized into the control group, TAA group(intraperitoneal injection of TAA at 300 mg·kg~(-1)), ICA group(gavage of ICA at 600 mg·kg~(-1)) and TAA + ICA group(intraperitoneal injection of TAA at 300 mg·kg~(-1) and gavage of ICA at 600 mg·kg~(-1)). Administration was performed every other day for 6 weeks. Body weight and length of femur were recorded at execution. Pathological injury and osteoclast differentiation of femur were observed based on hematoxylin-eosin(HE) staining and TRAP staining, and the changes of bone metabolism-related indexes alkaline phosphatase(ALP), calcium(Ca), phosphorus(P), magnesium(Mg), and cross-linked N-telopeptide of type Ⅰ collagen(NTX-Ⅰ) in serum were detected. Three-point bending test and micro-CT were applied to evaluate the quality of femur, and Western blot to detect the levels of osteoclast-related proteins TRAP, cathepsin K, RANK, RANKL, p38, p-p38, ERK, p-ERK, JNK, p-JNK, c-Fos, and NFATc1. The results showed ICA could inhibit TAA-induced production of TRAP-positive cells, the expression of osteoclast-related proteins, and nuclear translocation of NFATc1. ICA alleviated the weight loss, reduction of femur length, and growth inhibition induced by TAA in SD rats. ICA ameliorated the decline of femur elastic modulus caused by TAA and significantly restored trabecular bone mineral density(BMD), trabecular pattern factor(Tb.Pf), trabecular number(Tb.N), trabecular thickness(Tb.Th), and structure model index(SMI), thus improving bone structure. Western blot results showed ICA suppressed femoral osteoclast differentiation induced by TAA through RANKL-p38/ERK-NFATc1 signaling pathway. ICA inhibits osteoclast differentiation and prevents TAA-induced osteolysis by down-regulating RANKL-p38/ERK-NFAT signaling pathway.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteolysis / Bone Resorption Type of study: Prognostic_studies Limits: Animals Language: Zh Journal: Zhongguo Zhong Yao Za Zhi Journal subject: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Year: 2022 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteolysis / Bone Resorption Type of study: Prognostic_studies Limits: Animals Language: Zh Journal: Zhongguo Zhong Yao Za Zhi Journal subject: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Year: 2022 Document type: Article Affiliation country: Country of publication: